Novel alkynylphosphonate analogue of calcitriol with potent antiproliferative effects in cancer cells and lack of calcemic activity

ACS Medicinal Chemistry Letters

Volumn 2, Issue 7, 2011, Pages 503-508

  Salomón, Débora G ^a   Grioli, Silvina M ^a   Buschiazzo, Maximiliano ^a   Mascaró, Evangelina ^b   Vitale, Cristian ^b   Radivoy, Gabriel ^b   Perez, Manuel ^c   Fall, Yagamare ^c   Mesri, Enrique A ^d   Curino, Alejandro C ^a   Facchinetti, María M ^a  

^a Instituto de Investigaciones Bioquimicas Bahia Blanca   (Argentina)

^b UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^c UNIVERSITY OF VIGO   (Spain)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

1 ,25 (OH) 2 vitamin D 3; alkynylphosphonate analogues; cancer; cellular proliferation; hypercalcemia

Indexed keywords

[1,3 DIHYDROXY 9,10 SECOCHOLA 5,7,10(19) TRIEN 23 IN 24 YL]; CALCITRIOL DERIVATIVE; CALCIUM; CARBON; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL; CANCER CELL CULTURE; CHEMICAL BOND; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 79960431411     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200034w     Document Type: Article

References (26)

1. Bouillon, R.; Okamura, W. H.; Norman, A. W. Structure-function relationships in the vitamin D endocrine system Endocr. Rev. 1995, 16, 200-257
2. Jones, G.; Strugnell, S. A.; DeLuca, H. F. Current understanding of the molecular actions of vitamin D Physiol. Rev. 1998, 78, 1193-1231 (Pubitemid 28491953)
3. Eelen, G.; Verlinden, L.; De Clercq, P.; Vandewalle, M.; Bouillon, R.; Verstuyf, A. Vitamin D analogs and coactivators Anticancer Res. 2006, 26, 2717-2721 (Pubitemid 44155553)
4. Beer, T. M.; Myrthue, A. Calcitriol in cancer treatment: from the lab to the clinic Mol. Cancer Ther. 2004, 3, 373-381 (Pubitemid 39193713)
5. Trump, D.; Muindi, J.; Fakih, M.; Yu, W.; Johnson, C. Vitamin D compounds: Clinical development as cancer therapy and prevention agents Anticancer Res. 2006, 26, 2551-2556 (Pubitemid 44155534)
6. Brown, A. J.; Slatopolsky, E. Vitamin D analogs: Therapeutic applications and mechanisms for selectivity Mol. Aspects Med. 2008, 29, 433-452
7. Dalhoff, K.; Dancey, J.; Astrup, L.; Skovsgaard, T.; Hamberg, K. J.; Lofts, F. J.; Rosmorduc, O.; Erlinger, S.; Bach Hansen, J.; Steward, W. P.; Skov, T.; Burcharth, F.; Evans, T. R. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma Br. J. Cancer 2003, 89, 252-257 (Pubitemid 36976311)
8. Steinmeyer, A.; Schwarz, K.; Haberey, M.; Langer, G.; Wiesinger, G. Synthesis and biological activities of a new series of secosteroids: vitamin D phosphonate hybrids Steroids 2001, 66, 257-266 (Pubitemid 32140903)
9. Dauben, W. G.; Ollman, R.; Funhoff, A. S.; Neidlen, R. The synthesis of 25-oxo-25 phosphavitamin D3 Tetrahedron Lett. 1991, 32, 4643-4646
10. Uskokovic, M. R.; Norman, A. W.; Maanschand, P. S.; Studzinski, G. P.; Campbell, M. J.; Koeffler, H. P.; Takeuchi, A.; Siu-Caldera, M. L.; Rao, D. S.; Reddy, G. S. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways Steroids 2001, 66, 463-471 (Pubitemid 32140923)
11. 2 J. Org. Chem. 1986, 51, 1264-1269 (Pubitemid 16086283)
12. 3 J. Org. Chem. 1983, 48, 1414-1417
13. 3 by the dienyne route Tetrahedron 1997, 53, 4703-4714 (Pubitemid 27128869)
14. Corey, E. J.; Fuchs, P. L. A synthetic method for formyl→ethynyl conversion (RCHO→RC≡CH or RC≡CR′) Tetrahedron Lett. 1972, 13, 3769-3772
15. Wang, L.; Shen, W. The stille reaction of 1,1-Dibromo-1-alkenes: preparation of trisubstituted alkenes and internal alkynes J. Org. Chem. 1999, 64, 8873-8879 (Pubitemid 129599399)
16. Gil, J. M.; Sung, J. W.; Park, C. P.; Oh, D. Y. One-pot synthesis of 1-alkynylphosphonates Synth. Commun. 1997, 27, 3171-3174 (Pubitemid 27337364)
17. Trump, D. L.; Deeb, K. K.; Johnson, C. S. Vitamin D: Considerations in the continued development as an agent for cancer prevention and therapy Cancer J. 2010, 16, 1-9
18. Moreno, J.; Krishnan, A. V.; Feldman, D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer J. Steroid Biochem. Mol. Biol. 2005, 97, 31-36 (Pubitemid 41546211)
19. Muindi, J. R.; Yu, W. D.; Ma, Y.; Engler, K. L.; Kong, R. X.; Trump, D. L.; Johnson, C. S. CYP24A1 inhibition enhances the antitumor activity of calcitriol Endocrinology 2010, 151, 4301-4312
20. Garcion, E.; Wion-Barbot, N.; Montero-Menei, C. N.; Berger, F.; Wion, D. New clues about vitamin D functions in the nervous system Trends Endocrinol. Metab. 2002, 13, 100-105 (Pubitemid 36733998)
21. Skowronski, R. J.; Peehl, D. M.; Feldman, D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines Endocrinology 1993, 132, 1952-1960 (Pubitemid 23133240)
22. Anderson, M. G.; Nakane, M.; Ruan, X.; Kroeger, P. E.; Wu-Wong, J. R. Expression of VDR and CYP24A1 mRNA in human tumors Cancer Chemother. Pharmacol. 2006, 57, 234-240 (Pubitemid 41779843)
23. Diesel, B.; Radermacher, J.; Bureik, M.; Bernhardt, R.; Seifert, M.; Reichrath, J.; Fischer, U.; Meese, E. Vitamin D3 metabolism in human glioblastoma multiforme: Functionality of CYP27B1 splice variants, metabolism of Calcidiol, and effect of Calcitriol Clin. Cancer Res. 2005, 11, 5370-5380 (Pubitemid 41060810)
24. Reichrath, S.; Müller, C. S.; Gleissner, B.; Pfreundschuh, M.; Vogt, T.; Reichrath, J. Notch- and vitamin D signaling in 1,25(OH)(2)D(3)-resistant glioblastoma multiforme (GBM) cell lines J. Steroid Biochem. Mol. Biol. 2010, 121, 420-424
25. Colston, K. W.; Hansen, M. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer Endocr.-Relat. Cancer 2001, 9, 45-59
26. Muindi, J. R.; Modzelewski, R. A.; Peng, Y.; Trump, D. L.; Johnson, C. S. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses Oncology 2004, 66, 62-66 (Pubitemid 38410681)